Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at

Analysts at began coverage on shares of Alimera Sciences (NASDAQ:ALIMGet Rating) in a research note issued on Monday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright increased their target price on Alimera Sciences from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, July 28th.

Alimera Sciences Stock Performance

NASDAQ ALIM opened at $4.25 on Monday. The company has a market capitalization of $29.73 million, a P/E ratio of -1.61 and a beta of 1.38. Alimera Sciences has a one year low of $3.94 and a one year high of $7.92. The stock has a 50 day moving average price of $5.38 and a 200-day moving average price of $5.68.

Institutional Trading of Alimera Sciences

A hedge fund recently bought a new stake in Alimera Sciences stock. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Alimera Sciences, Inc. (NASDAQ:ALIMGet Rating) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 250,000 shares of the biopharmaceutical company’s stock, valued at approximately $1,400,000. Healthcare of Ontario Pension Plan Trust Fund owned about 3.58% of Alimera Sciences as of its most recent SEC filing. 34.53% of the stock is owned by hedge funds and other institutional investors.

About Alimera Sciences

(Get Rating)

Alimera Sciences, Inc, a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.

Recommended Stories

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with's FREE daily email newsletter.